An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams

Author:

Mohammed Khadija SaidORCID,de Laurent Zaydah R.,Omuoyo Donwilliams O.ORCID,Lewa Clement,Gicheru Elijah,Cheruiyot Robinson,Bartilol BrianORCID,Mutua Shadrack,Musyoki Jennifer,Gumba HoraceORCID,Mwacharo Jedidah,Riako Debra,Mwangi Shaban J.ORCID,Gichuki Bonface M.ORCID,Nyamako Lydia,Karani Angela,Karanja HenryORCID,Mugo Daisy,Gitonga John N.ORCID,Njuguna Susan,Gumbi Wilson,Tawa Brian,Tendwa Metrine,Cheruiyot Wesley,Sein Yiakon,Nyambu John K.,Patta Shem O.,Thani Thani Suleiman,Maitha Eric K.,Kitole Benson,Mwakinangu Mohamed S.,Muslih Barke S.,Otieno John Ochieng,Nyiro Joyce U.ORCID,Kiyuka Patience,Ndwiga LeonardORCID,Wamae KevinORCID,Kimani DomtilaORCID,Makale JohnstoneORCID,Morobe John MwitaORCID,Osoti Victor,Lambisia Arnold W.ORCID,Odundo Calleb,Mwarumba Salim,Mutunga Martin,Bejon PhilipORCID,Tsofa BenjaminORCID,Agoti Charles N.ORCID,Ochola-Oyier Lynette Isabella

Abstract

Background: The COVID-19 pandemic relies on real-time polymerase chain reaction (qRT-PCR) for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), to facilitate roll-out of patient care and infection control measures. There are several qRT-PCR assays with little evidence on their comparability. We report alterations to the developers’ recommendations to sustain the testing capability in a resource-limited setting. Methods: We used a SARS-CoV-2 positive control RNA sample to generate several 10-fold dilution series that were used for optimization and comparison of the performance of the four qRT-PCR assays: i) Charité Berlin primer-probe set, ii) European Virus Archive – GLOBAL (EVAg) primer-probe set, iii) DAAN premixed commercial kit and iv) Beijing Genomics Institute (BGI) premixed commercial kit. We adjusted the manufacturer- and protocol-recommended reaction component volumes for these assays and assessed the impact on cycle threshold (Ct) values. Results: The Berlin and EVAg E gene and RdRp assays reported mean Ct values within range of each other across the different titrations and with less than 5% difference. The DAAN premixed kit produced comparable Ct values across the titrations, while the BGI kit improved in performance following a reduction of the reaction components. Conclusion: We achieved a 2.6-fold and 4-fold increase in the number of tests per kit for the commercial kits and the primer-probe sets, respectively. All the assays had optimal performance when the primers and probes were used at 0.375X, except for the Berlin N gene assay. The DAAN kit was a reliable assay for primary screening of SARS-CoV-2 whereas the BGI kit’s performance was dependent on the volumes and concentrations of both the reaction buffer and enzyme mix. Our recommendation for SARS-CoV-2 diagnostic testing in resource-limited settings is to optimize the assays available to establish the lowest volume and suitable concentration of reagents required to produce valid results.

Funder

PATH

Department for International Development, UK Government

National Institute for Health Research

Wellcome Trust

DELTAS Africa Initiative

Publisher

F1000 Research Ltd

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3